CTOs on the Move

WithMe Health

www.withmehealth.com

 
WithMe Health replaces an employer`s pharmacy benefit manager (PBM) with a personalized medication guidance solution that greatly improves on and expands the scope of services available in the market today. Our modern technology and rich datasets allow consistent application of proven science to create individualized medication experiences for employees and their families that are proactive, adaptive, convenient and engaging. With an innovative, outcomes-oriented business model that aligns interests across the pharmaceutical value chain, WithMe Health optimizes health outcomes and value while substantially reducing costs for employers.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

WithMe Health raised $20M on 11/24/2020

Similar Companies

Vantage Holding Company

Vantage Holding Company is a Meadville, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bingham Memorial Hospital

Bingham Memorial Hospital is committed to quality patient care and recognizes that quality care requires a talented and experienced staff of professionals in our organization.

RSi FocalSearch

RSi FocalSearch is a Englewd Clfs, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bill Wilson Center

Bill Wilson Center is committed to working with the community to ensure that every youth has access to the variety of services needed to grow to be healthy and self-sufficient adults.

Bioatla

BioAtla was founded in 2007 and employs deep expertise in protein engineering to develop better monoclonal antibody and other protein therapeutics. Our suite of proprietary technologies (protected by more than 70 issued patents and patent applications) has enabled us to develop dozens of novel therapeutic proteins for our partners and our own pipeline. We accelerate the process from target discovery to manufacturing and preclinical studies by creating drugs with more selective targeting, greater affinity, and more cost-efficient and predictable manufacturing. In the process we also create valuable, protectable IP that gives our partners significant competitive advantage. The culmination of our protein evolution technologies is our Conditionally Active Biologics (CAB)platform. Monoclonal antibodies or enzymes can be engineered for selective conditional activation, i.e. the protein`s functions are designed to modulate with changes in microphysical conditions (e.g., pH level, oxidation, temperature, pressure concentration, presence of certain ions, hydrophobicity and competing protein binding). Tumors and other kinds of diseased tissue give rise to unique localized conditions distinct from normal tissue. CAB designed monoclonal antibodies can be programmed to deliver an ADC payload and/or recruit the immune response to specific sites and conditions in the body.